SCHEDULE: Moti Investments Discloses 6.1% Stake in Elicio Therapeutics

Moti Investments LLC has reported beneficial ownership of 1,408,892 shares, representing 6.1% of the outstanding common stock of Elicio Therapeutics, Inc.

Summary

• Moti Investments LLC has filed a Schedule 13G, indicating it beneficially owns 1,408,892 shares of Elicio Therapeutics, Inc. common stock.
• This ownership stake represents 6.1% of the class of securities.
• The filing indicates Moti Investments LLC has sole voting power and sole dispositive power over these shares.
• The filing date is July 16, 2026, with the event requiring the filing occurring on July 1, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports an existing ownership stake without providing new operational or financial performance data.

Positives

• Moti Investments LLC has taken a significant stake, holding 6.1% of Elicio Therapeutics' common stock.
• The reporting entity has sole voting and dispositive power, indicating clear control over its investment.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings typically indicate passive investment stakes by institutional investors or other entities. The disclosure by Moti Investments LLC suggests a notable interest in Elicio Therapeutics, a biotechnology company, which could be driven by the company's development pipeline or market position.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by Moti Investments LLC may signal increased institutional interest or potential influence on the company's stock.

Key Dates

Keywords

Elicio Therapeutics, Moti Investments LLC, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment, Saint Kitts and Nevis